Participants: Adults over the age of 60
Dosage: 3,750 mg of niacin twice daily (after gradual dose increase), 150 mg of dihydroberberine twice daily, 50 mg of taxifolin (with 500 mg of vitamin C and 15 mg of zinc) twice daily, 50 mg of tocotrienols twice daily

A combination of supplements, including the NAD+ precursor nicotinic acid, improves cholesterol, allowing some participants to cease taking statins.  

Study conducted by Professor Emeritus Joseph Keenan, MD, at the University of Minnesota. 

Nicotinic Acid

Participants: Healthy middle-aged to older adults (average age: ~53 years)
Dosage: 1,000 mg/day of urolithin A for 28 days

Supplementing healthy adults with urolithin A —a compound produced by our gut bacteria— counters signs of age-related immune system decline.  

Principal investigator Dr. Florian R. Greten (image: hessen-schafft-wissen.de).

Immunity

The Latest Insight on Anti-Aging Therapeutics Targeting Cardiovascular Disease

According to French scientists, no organ system appears as vulnerable to aging as the cardiovascular system, and anti-aging therapeutics may help mitigate the effects of cardiovascular disease.

(The principal investigator behind the review, aging researcher Guido Kroemer | Olympiad in Cardiovascular Medicine)

Anti-aging therapeutics may prevent and slow age-related cardiovascular dysfunction.

Cardiovascular

Model: Ten-month-old male EFAD mice 
Dosage: 14.4 ppm of alfatradiol in diet for five months

USC Study: Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer's

The drug alfatradiol, also known as 17ɑ-estradiol, reduces cognitive errors on a test of memory and lowers neuronal plaques in mice genetically predisposed to Alzheimer’s disease.

(The University of Southern California | College Matchpoint)

Researchers unveil data suggesting the drug alfatradiol improves signs of frailty, reduces cognitive errors, and reduces neuronal plaques in mice with a genetic predisposition to Alzheimer’s disease.

Brain &amp; Neurons

Model: UM-HET3 mice and 5XFAD mice 
Dosage: UM=HET3 mice received 180 mg/kg canagliflozin in chow starting at seven months of age, and FXFAD mice received 180 mg/kg canagliflozin in chow beginning at three months of age

New Study: Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression

The diabetes drug canagliflozin improves learning and memory in middle-aged male mice and reduces brain plaques in Alzheimer’s model mice.

The FDA-approved diabetes medication canagliflozin improves cognition in a mouse model of Alzheimer’s disease in males only.

Search Result: middle-age

NAD+ Boosting Supplement Challenges Cholesterol-Lowering Statins in Anti-Aging Research

Urolithin Supplement Counters Immune System Aging, New Human Trial Shows

The Latest Insight on Anti-Aging Therapeutics Targeting Cardiovascular Disease

USC Study Suggests Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer’s

Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression, Suggests New Study